Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
Cosmo Pharmaceuticals N.V. (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022.
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
Cosmo Pharmaceuticals N.V. (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022.
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that its fully owned subsidiary Cosmo Intelligent Medical Devices – IMD is expanding its cooperation with Medtronic, the world’s largest healthcare technology provider, to accelerate the development of Artificial Intelligence (AI) in the healthcare system and bring new AI-based solutions into patient care.
Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its preliminary unaudited results for the financial year 2022.
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clascoterone) cream 1% in Southeast Asia.
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK).
Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis
Cosmo Pharmaceuticals N.V. (“Cosmo”) announces that the FDA has granted the orphan-drug designation request of rifamycin for treatment of pouchitis.
GI Genius™ named to FORTUNE 2022 “Change the World” list
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that Medtronic, its global partner for GI GeniusTM, published a media release that GI Genius™ intelligent endoscopy module has been named to the prestigious FORTUNE 2022 “Change the World” list.
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI GeniusTM intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that Medtronic, its global partner for GI GeniusTM, published a media release that it has been awarded a contract for its Gastrointestinal Business Unit, through partnership with a Service-Disabled Veteran-Owned Small Businesses (SDVOSB), to install 115 Medtronic GI Genius™ intelligent endoscopy modules at numerous VA medical facilities across the country. Through this contract, veterans will have access to artificial intelligence (AI) technology that has been proven to improve the accuracy of polyp detection in colonoscopy screening.
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
Cosmo Pharmaceuticals N.V. (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, Italy and Austria.
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million up 338.2% (H1 2021: €3.4 million), operating profit of €8.1 million (H1 2021: €0.008 million), profit before tax €9.0 million (H1 2021: loss before tax €4.7 million) and reaffirms 2022 full-year guidance.
dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz